Abstract
Drug resistance in B cell leukemia is characterized by the co-expression of CXCR5 and CXCR3 chemokine receptors, making it a valuable biomarker for patient stratification. Herein we report a novel platform of activatable chemokines to selectively image drug-resistant leukemic B cells for the first time. The C-terminal derivatization of the human chemokines CXCL13 and CXCL10 with bioorthogonal tetrazine-BODIPY and BCN groups retained binding and internalization via their cognate CXCR5 and CXCR3 receptors and enabled rapid fluorescence labeling of CXCR5+ CXCR3+ resistant B cells -but not drug-susceptible leukemic cells- via intracellular chemokine ligation. This modular chemical approach offers a versatile strategy for real-time immunophenotyping of cell populations with distinct chemokine profiles and will accelerate the design of new precision medicine tools to advance personalized therapies in blood tumors.
Original language | English |
---|---|
Pages (from-to) | 30565-30572 |
Journal | Journal of the American Chemical Society |
Volume | 146 |
Issue number | 44 |
DOIs | |
Publication status | Published - 6 Nov 2024 |
Keywords / Materials (for Non-textual outputs)
- Boron Compounds/chemistry
- Humans
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Leukemia, B-Cell/drug therapy
- Chemokines/metabolism
- Molecular Structure